Sunday, 20 September 2026European Markets

CARASENT Stock 33.1% Up On Monday

Loading stream...

(VIANEWS) - The Market ended the session with CARASENT (CARA.OL) jumping 33.1% to kr19.05 on Monday while Oslo Børs Benchmark Index_GI rose 0.15% to kr1,367.92.

CARASENT's last close was kr14.30, 39.53% under its 52-week high of kr23.65.

About CARASENT

Carasent ASA provides cloud based electronic health record solutions to the health care industry in Sweden, Norway, and internationally. The company offers Webdoc, a cloud-based EHR system; Metodika EPM, a solution designed for mid-to-large-sized organizations; Medrave M4 to give healthcare staff and managers an overview and clear picture of the patient group being treated; Health Profile Institute AB (HPI), an occupational care platform; Ad Curis, a record system with digital services tailored for the specialist healthcare service with clients in rehabilitation, interdisciplinary specialized drug treatment, and mental health care, as well as businesses in care and prevention; and Ad Opus, a journal system for follow-up of participants in measures. It also provides platform services, such as Vårdrummet, Confrere, Ad Voca, electronic letters, SMS services, portal to medical services, and consulting and other services. The company was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. Carasent ASA was founded in 1997 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, CARASENT has a trailing twelve months EPS of kr-0.6.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.05%.

Moving Average

CARASENT's value is way higher than its 50-day moving average of kr15.55 and way above its 200-day moving average of kr16.10.

Yearly Top and Bottom Value

CARASENT's stock is valued at kr19.05 at 22:32 EST, way below its 52-week high of kr23.65 and way above its 52-week low of kr13.50.

More news about CARASENT (CARA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com